CD19 CAR-T治疗后侵袭性真菌感染:DESCAR-T登记研究
基于法国DESCAR-T登记的多中心队列研究,纳入2018至2022年1012例接受CD19 CAR-T治疗的复发/难治B细胞淋巴瘤成人患者,32例(3.1%)发生侵袭性真菌感染(IFI),中位起病时间29.5天,IFI相关死亡率为21.8%,多因素分析识别出高龄、既往治疗线数、既往异基因造血干细胞移植、抗IL-1受体拮抗剂治疗及IFI前细菌感染等危险因素。
要点
- CD19 CAR-T后IFI发生率为3.1%,中位起病时间29.5天。
- IFI相关死亡率为21.8%,曲霉病和念珠菌血症最常见。
- 高龄、既往治疗线数多、既往异基因移植等为危险因素。
核心结论
- 尽管CD19 CAR-T治疗后B细胞淋巴瘤患者IFI发生率低,但感染相关死亡率高,强调对高危患者需个体化预防和快速诊断。
研究设计与样本
- 多中心队列研究,通过法国DESCAR-T登记纳入2018至2022年1012例接受CD19 CAR-T治疗的复发/难治B细胞淋巴瘤成人患者,回顾性收集临床和生物学数据,IFI按EORTC标准分类。
主要发现
- 1012例患者中32例(3.1%)发生IFI,其中确诊14例、很可能12例、可能6例。
- IFI中位起病时间为29.5天(IQR 16.5-79.5天)。
- 最常见霉菌感染为侵袭性曲霉病(11/32),最常见酵母菌感染为念珠菌血症(12/32)。
- IFI患者相关死亡率为21.8%(7/32)。
- 多因素分析显示IFI相关危险因素包括高龄、既往治疗线数、既往异基因造血干细胞移植、抗IL-1受体拮抗剂治疗及IFI前细菌感染。
临床怎么用
- 对接受CD19 CAR-T治疗的B细胞淋巴瘤患者,尤其具有高龄、多线治疗、既往异基因移植等高危因素者,应考虑个体化抗真菌预防和快速诊断。
局限性
- 回顾性研究设计可能引入偏倚;IFI事件数较少(32例),风险因素分析效能有限;数据来自单一国家登记,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe the landscape of invasive fungal infections (IFIs) after chimeric antigen receptor (CAR) T-cell therapy for B-cell malignancies from the French national DESCAR-T registry and evaluate risk factors associated with invasive fungal infections in this population. METHODS: We conducted a multicentre cohort study to describe the landscape of IFIs in adults with relapsed or refractory B-cell lymphoma treated with CD19 CAR T-cell therapy. Patients were identified through the French DESCAR-T registry. Clinical and biological data were collected retrospectively. Each IFI was classified according to the European Organization for Research and Treatment of Cancer (EORTC) criteria. RESULTS: Among the 1012 patients included in the registry from 2018 to 2022, 32 patients (3.1%) presented with proven (n = 14/32), probable (n = 12/32), or possible (n = 6/32) IFIs. The median time to onset was 29.5 days (IQR 16.5-79.5 days). The most frequent mould infection was invasive aspergillosis, occurring in 11 of 32 patients, whereas the most frequent yeast infection was candidemia occurring in 12 of 32 patients. The IFI-related mortality rate among infected patients was 21.8% (7/32 patients). Multivariate analysis identified several risk factors associated with IFIs: advanced age, number of prior lines of therapy, prior allogeneic haematopoietic cell transplantation, antiinterleukin-1 receptor antagonist treatments, and pre-IFI bacterial infection. The median overall survival of patients with IFIs was 6 months (95% CI, 1.0-20.6) compared with 25.4 months (95% CI, 20.5-32.0) in the noninfected population. The median progression-free survival of patients with IFIs was 3.2 (95% CI, 0.8-18.3) months compared with 5.8 months (95% CI, 4.5-6.7) in the noninfected population. CONCLUSIONS: Despite the low incidence of IFI in B-cell lymphoma patients treated with CD19 CAR T-cell therapy, the high infectious mortality underscore the need for individualized prophylaxis and rapid diagnosis for high-risk patients.
引用
- Bouvier A, Durand A, Dupont V, et al. Invasive fungal infections after CD19 chimeric antigen receptor T-cell therapy for B-cell lymphoma: a Lymphoma study association study from the DESCAR-T (Dispositif d'Enregistrement et Suivi des patients traités par CAR-T cells) registry. Clin Microbiol Infect. 2025. PMID: 41109429. doi:10.1016/j.cmi.2025.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。